Category

Research
Nichola Oakenfull is partially vaccinated against Covid-19, but she’s still scared. The Wellington woman was diagnosed with multiple myeloma (a type of blood cancer) during alert level 3 last year – a diagnosis that may reduce the efficacy of the Pfizer vaccine. “It is very scary because I’m doing as much as I can to try and keep myself safe, but you are relying...
Continue Reading
This article originally published on The Limbic Most parents of children undergoing active cancer treatment at the RCH Children’s Cancer Centre, Melbourne last year reported no change to their child’s care due to COVID-19. An online survey of more than 100 parents in October-November 2020 found 69% reported no change to their child’s treatment plan...
Continue Reading
Pomalidomide (Pomalyst) in combination with bortezomib and dexamethasone (PVd) will be reimbursed on the PBS from 1 October for patients with relapsed or refractory  multiple myeloma who have received at least one prior treatment regimen including lenalidomide. According to distributor Bristol Myers Squibb, the thalidomide analogue was approved based on findings from the OPTIMISMM trial...
Continue Reading
People with blood cancers who are immunocompromised are now advised to have a third primary dose of COVID-19 vaccine with an mRNA vaccine. On 8 October the Australian Technical Advisory Group on Immunisation (ATAGI) recommended a booster third dose of vaccine as part of the primary course in individuals who are severely immunocompromised to address the risk...
Continue Reading
This article was originally posted on Stuff Around 21,000 Kiwis are living with blood cancer. Symptoms can be difficult to recognise, and experts worry that some people aren’t getting diagnosed as our health system tackles the impact of Covid-19. Hayley McLarin investigates. Neil Brownlie has beaten blood cancer three times in a decade. The former...
Continue Reading
This article was originally published on The Limbic Patients with blood cancer – including leukaemia, myeloma, and lymphoma – experience higher psychological distress from risk of COVID-19 infection and unmet needs, finds new research Over a year into the pandemic, we have all felt the effects at this point. But the disruptions and stress haven’t...
Continue Reading
This article was originally posted on The Limbic Addition of isatuximab to carfilzomib–dexamethasone has been hailed “a new standard of care” for patients with relapsed multiple myeloma. The anti-CD38 monoclonal antibody is already approved in combination with pomalidomide and dexamethasone in many countries for relapsed and refractory multiple myeloma. The phase 3 IKEMA trial comparing...
Continue Reading
Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitating a redefinition of SMM and its risk stratification. We assembled a large cohort of SMM patients meeting the revised IMWG criteria to develop a new...
Continue Reading
This Policy Review presents the International Myeloma Working Group’s clinical practice recommendations for the treatment of relapsed and  refractory  multiple  myeloma.  Based  on  the  results  of  phase  2  and  phase  3  trials,  these  recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one  previous  line  of  therapy,  and  for  patients ...
Continue Reading
This article was originally posted on Cure Donna gives advice to other multiple myeloma patients about what she has learned from living with this disease and her various therapies. Cristina Gasparetto, MD: We talked about your quality of life. Sometimes patients, they listen to us as physicians, but they listen to patients more. What type of...
Continue Reading
1 2 3 8

Floor 7, 90 The Terrace
Wellington Central
New Zealand